The expression landscape and heterogeneity of nectin-4, HER2, and Trop-2 in urothelial carcinoma: clinicopathological correlations and implications for ADC-guided precision therapy - Summary - MDSpire
Advertisement
The expression landscape and heterogeneity of nectin-4, HER2, and Trop-2 in urothelial carcinoma: clinicopathological correlations and implications for ADC-guided precision therapy
To map the expression patterns and co-expression landscapes of Nectin-4, HER2, and Trop-2 in urothelial carcinoma (UC).
Approach:
Cohort Analysis: Analyzed 118 UC specimens, including matched pairs of primary tumors with adjacent normal tissues, carcinoma in situ, and lymph node metastases.
Expression Evaluation: Expression levels were evaluated via immunohistochemistry (IHC).
Statistical Analysis: Statistical analyses included the Wilcoxon signed-rank test, Mann–Whitney U test, and multivariable logistic regression.
Key Findings:
90.7% of patients exhibited high expression of at least one target.
56.8% showed multi-target co-expression.
HER2 and Trop-2 were significantly upregulated from carcinoma in situ to invasive carcinoma.
Nectin-4 tended to downregulate in metastases.
Trop-2 expression was significantly higher in the lower urinary tract compared to the upper urinary tract.
Interpretation:
The study reveals significant antigenic drift and anatomical expression biases during disease progression, advocating for dynamic, multi-site molecular profiling.
Limitations:
The study is retrospective and may not capture all variables influencing expression patterns.
The sample size may limit the generalizability of the findings.
Conclusion:
The findings provide a translational blueprint to optimize ADC sequencing and address heterogeneity-driven resistance, introducing the Δscore as a new metric for quantifying net antigenic gain.
